Identification

Name
Desmopressin
Accession Number
DB00035  (BTD00112, BTD00061, BIOD00112, BIOD00061)
Type
Small Molecule
Groups
Approved
Description

Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney [6]. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems.

Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH [2]. It has been employed clinically since 1972 and is available in various formulations including intranasal solution, intravenous solution, oral tablet and oral lyophilisate [3]. Desmopressin is indicated for the treatment of polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. It was also newly approved for the treatment of mild classical hemophilia and von Willebrand's disease for minor surgeries. The active ingredient in most formulations is desmopressin acetate.

Structure
Thumb
Synonyms
  • 1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin
  • 1-deamino-8-D-arginine vasopressin
  • 1-desamino-8-D-arginine vasopressin
  • dDAVP
  • Desmopresina
  • Desmopressine
  • Desmopressinum
Product Ingredients
IngredientUNIICASInChI Key
Desmopressin acetate1K12647SFC62288-83-9MLSVJHOYXJGGTR-IFHOVBQLSA-N
Desmopressin acetate trihydrateXB13HYU18U62357-86-2YNKFCNRZZPFMEX-XHPDKPNGSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DdavpSolution.1 mg/mLNasalSanofi Aventis1978-02-21Not applicableUs
DdavpInjection4 ug/mLIntravenousFerring Pharmaceuticals1984-03-30Not applicableUs
DdavpTablet.1 mg/1OralSanofi Aventis1995-09-06Not applicableUs
DdavpTablet.1 mg/1OralFerring Pharmaceuticals1995-09-06Not applicableUs
DdavpInjection4 ug/mLIntravenousFerring Pharmaceuticals1984-03-30Not applicableUs
DdavpSolution4 ug/mLIntravenousSanofi Aventis1984-03-30Not applicableUs
DdavpSpray.1 ug/mLNasalFerring Pharmaceuticals1978-02-21Not applicableUs
DdavpSpray.1 ug/mLNasalFerring Pharmaceuticals1978-02-21Not applicableUs
DdavpTablet.2 mg/1OralSanofi Aventis1995-09-06Not applicableUs
DdavpTablet.2 mg/1OralFerring Pharmaceuticals1995-09-06Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desmopressin acetateInjection4 ug/mLIntravenousTeva Parenteral Medicines, Inc.1997-11-01Not applicableUs
Desmopressin AcetateTablet.2 mg/1Oralbryant ranch prepack2011-08-15Not applicableUs
Desmopressin AcetateInjection, solution40 ug/10mLIntravenous; SubcutaneousSagent Pharmaceuticals2018-03-15Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2015-05-28Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralHeritage2014-08-14Not applicableUs
Desmopressin AcetateTablet.1 mg/1OralBlue Point Laboratories2017-04-30Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralTeva2006-01-272017-12-31Us00093 7317 01 nlmimage10 02360120
Desmopressin AcetateSolution.1 mg/mLNasalSun Pharma Global FZE2013-12-24Not applicableUs
Desmopressin AcetateTablet.2 mg/1OralAmerincan Health Packaging2015-09-152019-02-28Us
Desmopressin AcetateSolution.1 mg/mLNasalPhysicians Total Care, Inc.2006-05-22Not applicableUs
International/Other Brands
Adiuretin (Ferring) / DesmoMelt (Ferring) / Minirin / Stimate
Categories
UNII
ENR1LLB0FP
CAS number
16679-58-6
Weight
Average: 1069.217
Monoisotopic: 1068.426954962
Chemical Formula
C46H64N14O12S2
InChI Key
NFLWUMRGJYTJIN-NXBWRCJVSA-N
InChI
InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
IUPAC Name
(2S)-2-{[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-5-carbamimidamido-N-(carbamoylmethyl)pentanamide
SMILES
NC(=O)CC[[email protected]@H]1NC(=O)[[email protected]](CC2=CC=CC=C2)NC(=O)[[email protected]](CC2=CC=C(O)C=C2)NC(=O)CCSSC[[email protected]](NC(=O)[[email protected]](CC(N)=O)NC1=O)C(=O)N1CCC[[email protected]]1C(=O)N[[email protected]@H](CCCNC(N)=N)C(=O)NCC(N)=O

Pharmacology

Indication
  • Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal).

  • Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral).

  • Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral).

Structured Indications
Pharmacodynamics

By mimicking the actions of endogenous ADH, desmopressin acts as a selective agonist of V2 receptors expressed in the renal collecting duct (CD) to increase water re-absorption and reduce urine production. Desmopressin has been shown to be more potent than ADH in increasing plasma levels of factor VIII activity in patients with hemophilia and von Willebrand's disease Type I [8]. Desmopressin demonstrates markedly diminished pressor activity. Desmopressin administered intranasally has an antidiuretic effect about one-tenth that of an equivalent dose administered by injection [7].

Mechanism of action

Upon binding of desmopressin to V2 receptors in the basolateral membrane of the cells of the distal tubule and collecting ducts of the nephron, adenylyl cyclase is stimulated. The resulting intracellular cascades in the collecting duct lead to increased rate of insertion of water channels, called aquaporins, into the lumenal membrane and enhanced the permeability of the membrane to water [6].

TargetActionsOrganism
AVasopressin V2 receptor
agonist
Human
AVasopressin V1a receptorNot AvailableHuman
AVasopressin V1b receptorNot AvailableHuman
Absorption

Following nasal spray administration of 0.83 mcg and 1.66 mcg, median time to peak plasma concentrations (Tmax) was 0.25 and 0.75 hour, respectively [FDA Label]. The peak plasma concentration was approximately 4.00 (± 3.85) pg/mL and 9.11 (± 6.90) pg/mL, respectively [FDA Label]. The bioavailability of 1.5 mg/mL desmopressin administered by the intranasal route was between 3.3 and 4.1% [8].

The absolute bioavailability of orally administered desmopressin varies between 0.08% and 0.16% where the mean maximum plasma concentration is reached within 2 hours [9].

Volume of distribution

The distribution volume of orally administered desmopressin is 0.2 – 0.32 l/kg [9]. It is not reported to cross the blood-brain barrier.

Protein binding

Following radioiodination (125I) in the N-terminal, the fraction of plasma protein binding of desmopressin was reported to be 17.3 ± 1.5% in a pharmacokinetic study involving healthy subjects [5].

Metabolism

In vitro, in human liver microsome preparations, it has been shown that no significant amount of desmopressin is metabolised in the liver and thus human liver metabolism in vivo is not likely to occur [9].

Route of elimination

Desmopressin is mainly excreted in the urine. About 65% of the amount of desmopressin absorbed after oral administration could be recovered in the urine within 24 hours [9].

Half life

Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours [FDA Label]. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment [FDA Label]. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours [9].

Clearance
Not Available
Toxicity

Intravenous TDLo in humans is reported to be 0.3 µg/kg/10M [MSDS]. Desmopressin is associated with hyponatremia in case of overdose, which may require temporary or permanent discontinuation of the therapy depending on severity. The effects of hyponatremia include seizure, altered mental status (confusion, drowsiness or continuing headache), cardiac arrhythmias and worsening edema. Other signs of overdose may include oliguria and rapid weight gain due to fluid retention [FDA Label]. In case of overdose, reduce the dose or frequency of drug administration, or discontinue use if appropriate. Assessment of serum sodium and initiation of appropriate medical treatment is recommended.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Desmopressin.Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Desmopressin.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Desmopressin.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desmopressin.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Desmopressin.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Desmopressin.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Desmopressin.Approved, Withdrawn
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Desmopressin.Approved, Illicit
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Desmopressin.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desmopressin.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Desmopressin.Illicit
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin.Illicit, Withdrawn
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Desmopressin.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desmopressin.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Desmopressin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Desmopressin.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desmopressin.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Desmopressin.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Desmopressin.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desmopressin.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Desmopressin.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Desmopressin.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Desmopressin.Experimental, Illicit, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desmopressin.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Desmopressin.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Desmopressin.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desmopressin.Experimental, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Desmopressin.Illicit, Investigational, Vet Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Desmopressin.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desmopressin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desmopressin.Approved, Investigational, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.Approved, Investigational, Vet Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desmopressin.Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Desmopressin.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Desmopressin.Approved, Illicit
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Desmopressin.Approved, Investigational
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desmopressin.Investigational
DemeclocyclineThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Demeclocycline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin.Approved, Investigational
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Desmopressin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desmopressin.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Desmopressin.Approved, Investigational
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Desmopressin.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desmopressin.Approved, Vet Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Desmopressin.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desmopressin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desmopressin.Approved, Illicit
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Desmopressin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Desmopressin.Experimental
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Desmopressin.Withdrawn
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Desmopressin.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desmopressin.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Desmopressin.Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Desmopressin.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Desmopressin.Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Desmopressin.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desmopressin.Approved, Illicit
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desmopressin.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Desmopressin.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Desmopressin.Illicit, Vet Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desmopressin.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Desmopressin.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Desmopressin.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desmopressin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.Approved, Illicit, Investigational, Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Desmopressin.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Desmopressin.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Desmopressin.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Desmopressin.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Desmopressin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Desmopressin.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.Approved, Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.Approved, Investigational
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Desmopressin.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Desmopressin.Approved, Illicit, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Desmopressin.Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.Approved, Illicit
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desmopressin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Desmopressin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Desmopressin.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Desmopressin.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin.Investigational, Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Desmopressin.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desmopressin.Withdrawn
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Desmopressin.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desmopressin.Withdrawn
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desmopressin.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Desmopressin.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Desmopressin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desmopressin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desmopressin.Investigational
LithiumThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Desmopressin.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Desmopressin.Experimental
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Desmopressin.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desmopressin.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desmopressin.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desmopressin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Desmopressin.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desmopressin.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin.Approved, Investigational, Withdrawn
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desmopressin.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Desmopressin.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desmopressin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desmopressin.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Desmopressin.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desmopressin.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Desmopressin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin.Approved, Vet Approved
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Desmopressin.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desmopressin.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Desmopressin.Experimental
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Desmopressin.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desmopressin.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Desmopressin.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Desmopressin.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Desmopressin.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Desmopressin.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin.Approved, Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desmopressin.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Desmopressin.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Desmopressin.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Desmopressin.Experimental
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desmopressin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Desmopressin.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Desmopressin.Experimental
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Desmopressin.Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Desmopressin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desmopressin.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Desmopressin.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Desmopressin.Experimental
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Desmopressin.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.Approved, Experimental, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Desmopressin.Approved, Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desmopressin.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Desmopressin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desmopressin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Desmopressin.Investigational
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Desmopressin.Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desmopressin.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Desmopressin.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Desmopressin.Experimental
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Desmopressin.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desmopressin.Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Desmopressin.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desmopressin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Desmopressin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desmopressin.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Desmopressin.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Desmopressin.Experimental
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desmopressin.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desmopressin.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.Approved
TolvaptanThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Desmopressin.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Desmopressin.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desmopressin.Approved, Investigational, Withdrawn
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Desmopressin.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Desmopressin.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, "High purity desmopressin produced in large single batches." U.S. Patent US5674850, issued November, 1991.

US5674850
General References
  1. Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. [PubMed:11380629]
  2. Richardson DW, Robinson AG: Desmopressin. Ann Intern Med. 1985 Aug;103(2):228-39. [PubMed:3893256]
  3. Vande Walle J, Stockner M, Raes A, Norgaard JP: Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007 Sep;2(3):232-8. [PubMed:18690973]
  4. Agerso H, Seiding Larsen L, Riis A, Lovgren U, Karlsson MO, Senderovitz T: Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol. 2004 Oct;58(4):352-8. doi: 10.1111/j.1365-2125.2004.02175.x. [PubMed:15373927]
  5. Lundin S, Broeders A, Melin P: Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. Clin Endocrinol (Oxf). 1993 Sep;39(3):369-74. [PubMed:8222299]
  6. 32. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 399-400). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  7. DDVAP Nasal Spray FDA Label [Link]
  8. Stimate (desmopressin acetate) nasal spray FDA Label [Link]
  9. UKPAR for Desmopressin acetate 100mcg and 200mcg Tablets [Link]
External Links
Human Metabolome Database
HMDB0014260
KEGG Drug
D00291
KEGG Compound
C06944
ChemSpider
10481973
BindingDB
50205291
ChEBI
4450
ChEMBL
CHEMBL376685
Therapeutic Targets Database
DNC000526
PharmGKB
PA449237
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Desmopressin
ATC Codes
H01BA02 — Desmopressin
AHFS Codes
  • 68:28.00 — Pituitary
FDA label
Download (1.22 MB)
MSDS
Download (26.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentDyspnea / Haemorrhage / Tachycardia1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1Enrolling by InvitationDiagnosticHemophilia A1
2CompletedNot AvailableCancer, Breast1
2CompletedOtherColorectal Cancers / Rectal haemorrhage1
2CompletedTreatmentIntracerebral Hemorrhage1
2CompletedTreatmentNocturia1
2RecruitingTreatmentNocturia1
2TerminatedTreatmentNocturia1
2Unknown StatusTreatmentPostoperative Ecchymosis1
2, 3TerminatedTreatmentLeptospirosis1
2, 3TerminatedTreatmentNocturia1
3CompletedTreatmentCentral Diabetes Insipidus1
3CompletedTreatmentNocturia7
3CompletedTreatmentNocturnal Enuresis2
3CompletedTreatmentPrimary Nocturnal Enuresis1
3RecruitingTreatmentNocturnal Enuresis / Sickle Cell Disorders1
3TerminatedTreatmentNocturia / Obstructive Sleep Apnoea (OSA)1
3Unknown StatusTreatmentPain / Renal Colic1
4Active Not RecruitingPreventionC.Surgical Procedure; Cardiac / Disorders, Blood Coagulation1
4CompletedPreventionBlood Loss,Surgical / Hemorrhage / Postoperative Hemorrhages1
4CompletedPreventionPatients Undergoing Endoscopic Sinus Surgery1
4CompletedPreventionRenal Failure1
4CompletedTreatmentAcquired Von Willebrand Disease Secondary to Severe Aortic Stenosis / Heye´s Syndrome / Severe Aortic Stenosis1
4CompletedTreatmentEnuresis / Polyuria1
4CompletedTreatmentNocturia1
4CompletedTreatmentNocturnal Polyuria1
4CompletedTreatmentPrimary Nocturnal Enuresis1
4RecruitingDiagnosticMonosymptomatic Nocturnal Enuresis1
4RecruitingTreatmentChildren With Mild Hemophilia A / Mild Haemophilia A Without Inhibitor1
4RecruitingTreatmentEnuresis, Nocturnal1
4TerminatedTreatmentHemorrhage / Postoperative Blood Loss1
4TerminatedTreatmentParkinson's Disease (PD)1
4Unknown StatusTreatmentHypothermia Induced Impairment of Primary Haemostasis1
4Unknown StatusTreatmentNocturia1
4Unknown StatusTreatmentNocturnal Enuresis1
Not AvailableCompletedNot AvailableHead Injury Trauma Blunt1
Not AvailableCompletedNot AvailableNocturia Associated With Nocturnal Polyuria1
Not AvailableCompletedNot AvailablePlatelets Dysfunction1
Not AvailableCompletedBasic ScienceGender Difference in V2 Receptor Function in Response to dDAVP Infusion / Nocturia / Nocturnal Enuresis1
Not AvailableCompletedPreventionBlood Platelet Disorders / Disorders, Blood Coagulation / Hematologic Diseases / Hypermenorrhea / Von Willebrand 's disease Type 11
Not AvailableCompletedScreeningDiabetes Insipidus / Diabetes Insipidus, Neurohypophyseal1
Not AvailableCompletedTreatmentCoagulation Disorders / Liver Cirrhosis1
Not AvailableCompletedTreatmentDesmopressin / Hemodilution / Mild Hypothermia / NSAIDs / Platelets Dysfunction1
Not AvailableCompletedTreatmentRenal Colic1
Not AvailableRecruitingNot AvailableNocturia1
Not AvailableUnknown StatusNot AvailableAcquired Haemophilia1
Not AvailableUnknown StatusScreeningDiabetes Insipidus1
Not AvailableUnknown StatusTreatmentIdiopathic Scoliosis1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
  • Ferring pharmaceuticals inc
  • Bausch and lomb pharmaceuticals inc
  • Apotex inc richmond hill
  • Csl behring llc
  • Apotex inc etobicoke site
  • Teva pharmaceuticals usa
  • Watson laboratories inc
Packagers
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Arcola Laboratories
  • Bachem Inc.
  • Barr Pharmaceuticals
  • Bausch & Lomb Inc.
  • CSL Behring LLC
  • Ferring Pharmaceuticals Inc.
  • Hospira Inc.
  • Kaiser Foundation Hospital
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Promex Medical Inc.
  • Rechon Life Science AB
  • Sanofi-Aventis Inc.
  • Sicor Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
InjectionIntravenous4 ug/mL
SprayNasal.1 ug/mL
LiquidIntramuscular; Intravenous; Subcutaneous4 mcg
Tablet, orally disintegratingSublingual120 mcg
Tablet, orally disintegratingSublingual240 mcg
Tablet, orally disintegratingSublingual60 mcg
SolutionNasal.1 mg/mL
SolutionNasal0.1 mg
Aerosol, meteredNasal10 mcg
TabletOral0.1 mg
TabletOral0.2 mg
Injection, solutionIntravenous; Subcutaneous4 ug/mL
Injection, solutionIntravenous; Subcutaneous40 ug/10mL
SolutionIntravenous4 ug/mL
SprayNasal.1 mg/mL
SprayNasal10 ug/1
SprayNasal10 ug/.1mL
TabletOral.1 mg/1
TabletOral.2 mg/1
Spray, meteredNasal10 mcg
Tablet, orally disintegratingSublingual25 mcg
Tablet, orally disintegratingSublingual50 mcg
Spray, meteredNasal.83 ug/1
Spray, meteredNasal1.66 ug/1
LiquidIntravenous; Subcutaneous15 mcg
SprayNasal150 mcg
Spray, meteredNasal1.5 mg/mL
Prices
Unit descriptionCostUnit
Stimate 1.5 mg/ml nasal spray334.2USD ml
Ddavp 0.01% nasal spray50.76USD ml
Ddavp 4 mcg/ml ampul43.27USD ml
Desmopressin 0.1 mg/ml spray39.6USD ml
Ddavp 0.1 mg/ml Solution21.26USD ml
Octostim 150 mcg/dose Metered Dose Spray17.39USD dose
Ddavp 4 mcg/ml11.33USD ml
Desmopressin ac 4 mcg/ml amp7.28USD ml
Desmopressin ac 4 mcg/ml vial7.08USD ml
Ddavp 0.2 mg tablet6.43USD tablet
Ddavp 0.1 mg tablet4.47USD tablet
Desmopressin acetate 0.2 mg tablet4.44USD tablet
Desmopressin acetate 0.1 mg tablet3.08USD tablet
Ddavp 0.2 mg Tablet2.98USD tablet
Ddavp 10 mcg/dose Metered Dose Spray2.13USD dose
Apo-Desmopressin 0.2 mg Tablet1.67USD tablet
Novo-Desmopressin 0.2 mg Tablet1.67USD tablet
Pms-Desmopressin 0.2 mg Tablet1.67USD tablet
Ddavp 0.1 mg Tablet1.49USD tablet
Apo-Desmopressin 10 mcg/dose Metered Dose Spray1.48USD dose
Apo-Desmopressin 0.1 mg Tablet0.83USD tablet
Novo-Desmopressin 0.1 mg Tablet0.83USD tablet
Pms-Desmopressin 0.1 mg Tablet0.83USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7022340No2003-04-302023-04-30Us
US5500413No1993-06-292013-06-29Us
CA2484724No2007-01-162023-05-07Canada
CA2486833No2005-08-022024-04-30Canada
US9539302No2010-06-152030-06-15Us
US7799761No2004-09-262024-09-26Us
US7405203No2003-05-062023-05-06Us
US7579321No2003-05-062023-05-06Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.11 mg/mLALOGPS
logP-1ALOGPS
logP-6.1ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)9.5ChemAxon
pKa (Strongest Basic)11.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count15ChemAxon
Hydrogen Donor Count14ChemAxon
Polar Surface Area435.41 Å2ChemAxon
Rotatable Bond Count19ChemAxon
Refractivity279.78 m3·mol-1ChemAxon
Polarizability104.7 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7979
Blood Brain Barrier-0.8866
Caco-2 permeable-0.7612
P-glycoprotein substrateSubstrate0.8242
P-glycoprotein inhibitor INon-inhibitor0.7864
P-glycoprotein inhibitor IINon-inhibitor0.9237
Renal organic cation transporterNon-inhibitor0.5915
CYP450 2C9 substrateNon-substrate0.7833
CYP450 2D6 substrateNon-substrate0.7901
CYP450 3A4 substrateNon-substrate0.5497
CYP450 1A2 substrateNon-inhibitor0.8383
CYP450 2C9 inhibitorNon-inhibitor0.7906
CYP450 2D6 inhibitorNon-inhibitor0.8735
CYP450 2C19 inhibitorNon-inhibitor0.765
CYP450 3A4 inhibitorNon-inhibitor0.7663
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9331
Ames testNon AMES toxic0.6679
CarcinogenicityNon-carcinogens0.8428
BiodegradationNot ready biodegradable0.9445
Rat acute toxicity2.7183 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.83
hERG inhibition (predictor II)Inhibitor0.6036
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Oligopeptides
Alternative Parents
Cyclic peptides / Arginine and derivatives / Proline and derivatives / N-acyl-alpha amino acids and derivatives / Macrolactams / Alpha amino acid amides / Pyrrolidinecarboxamides / N-acylpyrrolidines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives
show 14 more
Substituents
Alpha-oligopeptide / Cyclic alpha peptide / Arginine or derivatives / N-acyl-alpha amino acid or derivatives / Proline or derivatives / Macrolactam / Alpha-amino acid amide / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / N-acylpyrrolidine
show 30 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name
AVPR2
Uniprot ID
P30518
Uniprot Name
Vasopressin V2 receptor
Molecular Weight
40278.57 Da
References
  1. Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12. [PubMed:18761325]
  2. Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. [PubMed:16333859]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behavi...
Gene Name
AVPR1A
Uniprot ID
P37288
Uniprot Name
Vasopressin V1a receptor
Molecular Weight
46799.105 Da
References
  1. Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26. [PubMed:10731046]
  2. Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. [PubMed:10594321]
  3. Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32. [PubMed:8957254]
  4. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.
Gene Name
AVPR1B
Uniprot ID
P47901
Uniprot Name
Vasopressin V1b receptor
Molecular Weight
46970.345 Da
References
  1. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460]
  2. Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72. [PubMed:14971638]
  3. Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. doi: 10.1016/S0079-6123(08)00440-8. [PubMed:18655906]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:16